Name: CLENE INC (CLNN) Stock
Brand: CLENE INC
Rating: 6.5 (3 reviews)

CLNN Latest News, Press Relases and Analysis

All

Press Releases

18 hours ago - By: Zacks Investment Research - Mentions: OCS

Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates

11 days ago - By: Benzinga - Mentions: BFLY ILMN PACB CRBP ...

12 Health Care Stocks Moving In Friday's Intraday Session

22 days ago - By: Clene Inc.

Clene to Present at the Emerging Growth Conference

a month ago - By: Clene Inc.

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

2 months ago - By: Clene Inc.

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease

2 months ago - By: Clene Inc.

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Benzinga - Mentions: NBY CLDX ALC CTSO ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

3 months ago - By: The Motley Fool

Clene Posts 70% Revenue Drop in Q2

3 months ago - By: Zacks Investment Research - Mentions: RNA

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: MGTX

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Clene Inc.

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

3 months ago - By: Clene Inc.

Clene to Present at the Emerging Growth Conference

3 months ago - By: Zacks Investment Research - Mentions: ABSI

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Clene Inc.

Clene to Present at the Canaccord 45th Annual Growth Conference

3 months ago - By: Zacks Investment Research - Mentions: CSTL

Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates

4 months ago - By: Clene Inc.

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

5 months ago - By: ACCESS Newswire - Mentions: MNRG.CA OPHC XHLD ROLR ...

Q2 Virtual Investor Summit: Presentations Available Now

5 months ago - By: Stocktwits - Mentions: TNMG GOSS RGBP BIXT ...

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

5 months ago - By: ACCESS Newswire

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

6 months ago - By: Zacks Investment Research - Mentions: GYRE

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: Clene Inc.

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

6 months ago - By: Zacks Investment Research - Mentions: CERT

Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates

7 months ago - By: Clene Inc.

Clene to Present at the Emerging Growth Conference

7 months ago - By: Clene Inc.

Clene to Present at the Jones Healthcare and Technology Innovation Conference

8 months ago - By: Clene Inc.

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

8 months ago - By: ACCESS Newswire - Mentions: DRTS GIFT VOXR FEMY ...

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

8 months ago - By: Clene Inc.

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

8 months ago - By: Clene Inc.

Clene to Present at the 37TH Annual Roth Conference

9 months ago - By: ACCESS Newswire

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

a year ago - By: Clene Inc.

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

a year ago - By: Clene Inc.

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

a year ago - By: Clene Inc.

CLENE INC (CLNN) Stock News

CLNN Latest News, Press Relases and Analysis

Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates

12 Health Care Stocks Moving In Friday's Intraday Session

Clene to Present at the Emerging Growth Conference

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Clene Posts 70% Revenue Drop in Q2

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Clene to Present at the Emerging Growth Conference

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

Clene to Present at the Canaccord 45th Annual Growth Conference

Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Q2 Virtual Investor Summit: Presentations Available Now

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates

Clene to Present at the Emerging Growth Conference

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Clene to Present at the 37TH Annual Roth Conference

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

Clene to Present at Upcoming October Conferences